NEMERA
20, Avenue de la Gare – 38290 LA VERPILLIERE
T: +33 4 74 94 06 54
E : information@nemera.net
W: www.nemera.net

As a world-leading drug delivery device solutions provider, Nemera’s goal of putting patients first enables it to design and manufacture devices that maximize treatment efficacy. Nemera is a holistic partner and helps its customers succeed in the sprint to market with its combination products. From early device strategy to state-of-the-art manufacturing, Nemera is committed to the highest quality standards. Agile and open-minded, the company works with its customers as colleagues. Together, they go the extra mile to fulfil its mission.

NEMERA IS YOUR HOLISTIC PARTNER FOR THE COMBINATION PRODUCT JOURNEY

From device selection through product lifecycle management, Nemera is your single partner for the whole of the combination product journey. By focusing on solutions that make patients’ lives easier and safer, Nemera has built a strong portfolio of innovative products and technologies. To complement the products portfolio, Nemera also offers end-to-end services and expertise in device development, device consulting, and contract manufacturing to help you through every step of the journey. Nemera applies this know-how and its singular focus on healthcare to realize its vision of becoming the most patient centric drug – device company in partnership with our customers.

OPHTHALMIC: A CLEAR VISION FOR EYE CARE

One of the main criticalities of self-administered eye care treatments today is poor patient adherence, especially with chronic diseases. We strive to improve patient experience by providing safe and effective multidose eyedroppers for preservative-free solutions, used all over the world: Novelia® is a preservative-free multidose eye dropper delivering consistent drops for better patient compliance.

NASAL, BUCCAL, AURICULAR: MAKE EVERY SPRAY COUNT

The number of drugs delivered through the ear, nose and throat is expanding. We provide a comprehensive range of pumps, compatible with a wide choice of actuators for each delivery route (ear, nose and throat), suitable for regulated and low regulated markets: multidose pump systems (SP270+, SP370+, SP27, SP37, In-vitro Bioequivalence for nasal sprays, Child-resistant solutions), unidose systems (UniSpray), Retronose®, and electronic technologies (Safe’n’Spray™ and Electronic Nasal device). We guarantee precision and dose consistency to maximize treatment efficacy and improve patients’ outcomes.

DERMAL: CONVENIENT FOR PATIENTS, PROTECTIVE FOR FORMULATIONS

The dermal application is a convenient non-invasive way to administer liquid sprays, lotions, gels, or creams to the skin for dermatological, anti-inflammatory or systemic treatments. Our airless and atmospheric delivery devices are suitable for RX and OTC formulations and have all the documentation needed to be registered on regulated markets: Sof’Bag®+, Sof’Airless, Spray pumps for vicous formulations and Child Resistant Closure systems.

PARENTERAL: COMPLEX DEVICES, SIMPLE PATIENT CARE

The growing prevalence of chronic diseases, along with the evolution of self-administration at home, is driving new ways of administrating parenteral drugs. As injecting a drug means increased risks of use errors and needlestick injuries, self-administration at home translates into a need for safer, easy-to-use and ergonomic devices. We are committed to ensure adherence and user well-being for patients and healthcare professionals providing a comprehensive parenteral product range that matches their need: Passive Safety Systems (Safe’n’Sound® 1ml and 2.25ml), Reusable and Disposable Pen platforms, Implanters, and Body injectors (Symbioze).

INHALATION: A BREATH OF EXPERTISE

From the concept idea to large scale manufacturing, we’re the utmost holistic partner to develop your inhalers. We help our customers succeed in the sprint to market with their formulations targeting the inhalation treatments. We also are an active contributor to the scientific community and we strive to consider in our research evolving trends in inhalation and in patient needs, as well as increasing interest to digital and sustainability related factors.